Anon SrikiatkhachornJames F. KelleyUniversity of Massachusetts Medical SchoolMahidol UniversityUniversity of Hawaii System2018-11-092018-11-092014-01-01Antiviral Research. Vol.109, No.1 (2014), 160-17018729096016635422-s2.0-84905189360https://repository.li.mahidol.ac.th/handle/20.500.14594/34056Therapies to prevent or reverse endothelial dysfunction and vascular leak found in dengue hemorrhagic fever (DHF) have not been identified. In this review we summarize dengue viruses and the spectrum of human disease and highlight evidence of endothelial cell dysfunction in DHF based on studies in patients and mouse and tissue culture models. Evidence suggests that both virus antigen and host immune response, can cause endothelial cell dysfunction and weaken endothelial barrier integrity. We suggest possible therapeutic interventions and highlight how therapies targeting altered endothelial function might be evaluated in animal models and in patients with DHF. © 2014 Elsevier B.V. All rights reserved.Mahidol UniversityImmunology and MicrobiologyPharmacology, Toxicology and PharmaceuticsReviewSCOPUS10.1016/j.antiviral.2014.07.005